These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17084544)

  • 1. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.
    Sylvester JE; Grimm PD; Wong J; Galbreath RW; Merrick G; Blasko JC
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):376-81. PubMed ID: 20864269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical relapse-free survival in 400 patients treated with I-125 prostate brachytherapy: the Guildford experience.
    Nobes JP; Wells IG; Khaksar SJ; Money-Kyrle JF; Laing RW; Langley SE
    Prostate Cancer Prostatic Dis; 2009; 12(1):61-6. PubMed ID: 18427571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience.
    Sylvester JE; Blasko JC; Grimm PD; Meier R; Malmgren JA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):944-52. PubMed ID: 14575824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
    Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
    Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
    J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
    Ragde H; Grado GL; Nadir BS
    Arch Esp Urol; 2001 Sep; 54(7):739-47. PubMed ID: 11692443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.